Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.40
Revised: November 25, 2013
Accepted: December 12, 2013
Published online: February 15, 2014
Core tip: Incretin therapy (glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors) combined with insulin therapy is a glucose-lowering strategy in type 2 diabetes. The combination allows a complementary mode of mechanistic action and, as demonstrated in several clinical trials, is glucose-lowering in association with limited risk for hypoglycemia and weight gain. The combination is a promising strategy in patients in whom metformin with either incretin therapy or basal insulin is insufficient for adequate glycemic control. This article reviews the background and clinical studies on this combination.